The disclosure is directed to compounds of Formula I, Formula II, Formula III, or Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII : Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
该披露涉及到Formula I、Formula II、Formula III或Formula IV、Formula V、Formula VI、Formula VII或Formula VIII的化合物:描述了它们在抑制
蛋白精氨酸甲基转移酶5(PR
MT5)酶和治疗疾病中的使用方法,以及它们的制备方法。